Accretion Pharmaceuticals Limited (NSE:ACCPL)
India · Delayed Price · Currency is INR 202.30
-5.70 (-2.74%)
At close: Aug 21, 2026
Accretion Pharmaceuticals Revenue
In the fiscal year ending March 31, 2026, Accretion Pharmaceuticals had annual revenue of 896.27M INR with 56.21% growth. Accretion Pharmaceuticals had revenue of 457.81M in the half year ending March 31, 2026.
Revenue
896.27M
Revenue Growth
+56.21%
P/S Ratio
2.51
Revenue / Employee
6.79M
Employees
132
Market Cap
2.25B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 896.27M | 322.51M | 56.21% |
| Mar 31, 2025 | 573.76M | 440.24M | 329.70% |
| Mar 31, 2024 | 133.53M | -161.79M | -54.79% |
| Mar 31, 2023 | 295.32M | 69.47M | 30.76% |
| Mar 31, 2022 | 225.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bilcare | 7.69B |
| Sat Kartar Life | 2.01B |
| Everest Organics | 1.92B |
| Gennex Laboratories | 1.78B |
| Astonea Labs | 1.48B |
| Kerala Ayurveda | 1.36B |
| Oxygenta Pharmaceutical | 1.35B |
| BDH Industries | 997.10M |